These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26772993)

  • 1. Idelalisib Bolsters CLL Regimen.
    Leslie M
    Cancer Discov; 2016 Mar; 6(3):OF2. PubMed ID: 26772993
    [No Abstract]   [Full Text] [Related]  

  • 2. BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
    Visentin A; Imbergamo S; Scomazzon E; Pravato S; Frezzato F; Bonaldi L; Pizzi M; Vio S; Gregianin M; Burei M; Facco M; Semenzato G; Piazza F; Trentin L
    Br J Haematol; 2019 Apr; 185(1):193-197. PubMed ID: 29974955
    [No Abstract]   [Full Text] [Related]  

  • 3. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
    Shah A; Mangaonkar A
    Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
    Morabito F; Gentile M; Seymour JF; Polliack A
    Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K-δ inhibitor produces long-lasting responses.
    Cancer Discov; 2013 Jul; 3(7):OF11. PubMed ID: 23847354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.
    Lampson BL; Kim HT; Davids MS; Abramson JS; Freedman AS; Jacobson CA; Armand PA; Joyce RM; Arnason JE; Rassenti LZ; Kipps TJ; Fein J; Fernandes SM; Hanna JR; Fisher DC; Brown JR
    Blood Adv; 2019 Apr; 3(7):1167-1174. PubMed ID: 30967392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.
    Betrian S; Ysebaert L; Heider KH; Delord JP; Fournié JJ; Quillet-Mary A
    Blood Cancer J; 2016 Nov; 6(11):e496. PubMed ID: 27834943
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
    Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
    Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.
    Thompson PA; Stingo F; Keating MJ; Ferrajoli A; Burger JA; Wierda WG; Kadia TM; O'Brien SM
    Cancer; 2016 Aug; 122(16):2505-11. PubMed ID: 27182988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idelalisib-related pneumonitis.
    Haustraete E; Obert J; Diab S; Abbes S; Zini JM; Valade S; Lerolle N; Albin N; Arnulf B; Bouaziz JD; Hussenet C; Tazi A; Bergeron A
    Eur Respir J; 2016 Apr; 47(4):1280-3. PubMed ID: 26917607
    [No Abstract]   [Full Text] [Related]  

  • 12. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
    Brown JR
    Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab.
    Gentile M; Martino EA; Visentin A; Coscia M; Reda G; Sportoletti P; Mauro FR; Laurenti L; Varettoni M; Murru R; Chiarenza A; Vigna E; Mendicino F; Lucia E; Bossio S; Recchia AG; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Al-Janazreh H; Vitale C; Tripepi G; D'Arrigo G; Angeletti I; Bomben R; Neri A; Cutrona G; Fronza G; Di Raimondo F; Gaidano G; Cuneo A; Foà R; Ferrarini M; Trentin L; Gattei V; Morabito F
    Blood Cancer J; 2020 Sep; 10(9):92. PubMed ID: 32938904
    [No Abstract]   [Full Text] [Related]  

  • 14. Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.
    Hock BD; MacPherson SA; McKenzie JL
    PLoS One; 2017; 12(3):e0172858. PubMed ID: 28257435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.
    Hewett YG; Uprety D; Shah BK
    J Oncol Pharm Pract; 2016 Apr; 22(2):284-8. PubMed ID: 25712626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.
    O'Brien SM; Lamanna N; Kipps TJ; Flinn I; Zelenetz AD; Burger JA; Keating M; Mitra S; Holes L; Yu AS; Johnson DM; Miller LL; Kim Y; Dansey RD; Dubowy RL; Coutre SE
    Blood; 2015 Dec; 126(25):2686-94. PubMed ID: 26472751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idelalisib for treatment of B-cell malignancies.
    Do B; Mace M; Rexwinkle A
    Am J Health Syst Pharm; 2016 Apr; 73(8):547-55. PubMed ID: 26933132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twice-daily pill could treat leukemia.
    Printz C
    Cancer; 2014 Aug; 120(15):2225. PubMed ID: 25047250
    [No Abstract]   [Full Text] [Related]  

  • 19. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia.
    Robak T; Blonski JZ; Robak P
    Semin Oncol; 2016 Apr; 43(2):280-90. PubMed ID: 27040707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
    Barr PM; Saylors GB; Spurgeon SE; Cheson BD; Greenwald DR; O'Brien SM; Liem AK; Mclntyre RE; Joshi A; Abella-Dominicis E; Hawkins MJ; Reddy A; Di Paolo J; Lee H; He J; Hu J; Dreiling LK; Friedberg JW
    Blood; 2016 May; 127(20):2411-5. PubMed ID: 26968534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.